These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23125170)

  • 1. Number needed to treat in COPD: exacerbations versus pneumonias.
    Suissa S
    Thorax; 2013 Jun; 68(6):540-3. PubMed ID: 23125170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Yates JC; Vestbo J;
    N Engl J Med; 2007 Feb; 356(8):775-89. PubMed ID: 17314337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
    Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
    N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
    Kardos P; Wencker M; Glaab T; Vogelmeier C
    Am J Respir Crit Care Med; 2007 Jan; 175(2):144-9. PubMed ID: 17053207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Number needed to treat in COPD: exacerbations versus pneumonias.
    Keene ON; Anzueto A; Ferguson GT; Calverley PM
    Thorax; 2013 Sep; 68(9):882. PubMed ID: 23503625
    [No Abstract]   [Full Text] [Related]  

  • 9. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
    Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
    Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
    Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.
    Crim C; Calverley PM; Anderson JA; Celli B; Ferguson GT; Jenkins C; Jones PW; Willits LR; Yates JC; Vestbo J
    Eur Respir J; 2009 Sep; 34(3):641-7. PubMed ID: 19443528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
    Fang LZ; Liang X; Zhang JQ; Liu L; Fu WP; Zhao ZH; Dai LM
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):811-4. PubMed ID: 19080533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Author's response to letter on number needed to treat in COPD: exacerbations versus pneumonias.
    Suissa S
    Thorax; 2013 Sep; 68(9):882-3. PubMed ID: 23935172
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis.
    Halpin DM
    Int J Clin Pract; 2005 Oct; 59(10):1187-94. PubMed ID: 16178987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients.
    Johnson M; Agusti AG; Barnes NC
    COPD; 2008 Dec; 5(6):369-75. PubMed ID: 19353351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salmeterol/fluticasone propionate combination in the treatment of COPD.
    Singh SD
    Expert Rev Respir Med; 2007 Aug; 1(1):25-33. PubMed ID: 20477262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological issues in therapeutic trials of COPD.
    Suissa S; Ernst P; Vandemheen KL; Aaron SD
    Eur Respir J; 2008 May; 31(5):927-33. PubMed ID: 18216056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Number needed to treat is incorrect without proper time-related considerations.
    Suissa D; Brassard P; Smiechowski B; Suissa S
    J Clin Epidemiol; 2012 Jan; 65(1):42-6. PubMed ID: 21816576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovations to achieve excellence in COPD diagnosis and treatment in primary care.
    Fromer L; Barnes T; Garvey C; Ortiz G; Saver DF; Yawn B
    Postgrad Med; 2010 Sep; 122(5):150-64. PubMed ID: 20861599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.